Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...

For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the ...

Supernus Pharmaceuticals (NASDAQ:SUPN) just reported results for the first quarter of 2024. The company did not report any EPS for the quarter. The company reported revenue of $143.64 million.

NASDAQ SUPN opened at $35.59 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The company has a 50 day moving average of $35.65 and a 200-day ...

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in ...

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 6.64M to 6.20M. This put 17.19% of the company's publicly available shares short.

Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and ...

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN ...